Eupraxia Pharmaceuticals Inc. (EPRX)
Automate Your Wheel Strategy on EPRX
With Tiblio's Option Bot, you can configure your own wheel strategy including EPRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EPRX
- Rev/Share 0.0
- Book/Share 0.7575
- PB 6.7246
- Debt/Equity 0.0018
- CurrentRatio 13.003
- ROIC -1.0128
- MktCap 193228266.0
- FreeCF/Share -0.8447
- PFCF -6.4103
- PE -7.3354
- Debt/Assets 0.0018
- DivYield 0
- ROE -1.2145
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | EPRX | H.C. Wainwright | -- | Buy | -- | $12 | June 26, 2025 |
| Initiation | EPRX | Canaccord Genuity | -- | Speculative Buy | -- | -- | June 16, 2025 |
| Initiation | EPRX | Craig Hallum | -- | Buy | -- | $12 | Feb. 21, 2025 |
News
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE)
Read More
Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE)
Read More
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
Histological scores and symptom scores continue to improve as EP-104GI dose, and area of esophageal coverage, increase Cohort 6 showed the greatest symptom relief scores ("SDI") of all cohorts to date at 12 weeks Cohort 6 had the greatest magnitude and percentage change in tissue health scores ("EoEHSS") of any cohort to date at 12 weeks Cohort 6 saw the greatest reduction in Peak Eosinophil Count ("PEC") of any cohort to date Cohort 5 demonstrated the greatest symptom score reduction (SDI) seen to date at 24 weeks, showing continuously improving symptom relief over that time For tissue health (EoEHSS) and …
Read More
Eupraxia Pharmaceuticals Announces CFO Succession
Published: February 18, 2025 by: PRNewsWire
Sentiment: Neutral
- Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the role VICTORIA, BC , Feb. 18, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has appointed Alex Rothwell as the Company's new Chief Financial Officer, effective immediately. Bruce Cousins, the Company's outgoing CFO, is retiring and will remain in a consultant role in the near-term to ensure an orderly transition of the CFO responsibilities.
Read More
About Eupraxia Pharmaceuticals Inc. (EPRX)
- IPO Date
- Website https://www.eupraxiapharma.com
- Industry Biotechnology
- CEO James A. Helliwell FRCPC,
- Employees 33